Contact
searchSearch
HMP Global
Login

Follicular Lymphoma Specialty Channel

Follicular Lymphoma
Specialty Channel
Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology
News
Odronextamab Demonstrates Durable Responses, Manageable Safety Among Patients With Heavily Pretreated R/R Follicular Lymphoma
09/26/2024
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a...
09/26/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma
05/16/2024

Amber Denham

Amber Denham
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug...
05/16/2024
Oncology
News
Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma
05/08/2024

Amber Denham

Amber Denham
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective...
05/08/2024
Oncology
Quiz
Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma
03/27/2024
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to...
03/27/2024
Oncology
FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
Quiz
Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy
02/05/2024
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from...
02/05/2024
Oncology
News
Prognostic Value of Minimal Residual Disease Among Previously Untreated Patients With Follicular Lymphoma
02/01/2024
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status...
02/01/2024
Oncology
Quiz
Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL
01/29/2024
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the...
01/29/2024
Oncology
News
Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL
01/22/2024
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested...
01/22/2024
Oncology
News
Mosunetuzumab Yields Clinically Beneficial Outcomes for Patients With Follicular Lymphoma Treated With 3 or More Lines of Therapy
01/19/2024
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that...
01/19/2024
Oncology

News

News
Odronextamab Demonstrates Durable Responses, Manageable Safety Among Patients With Heavily Pretreated R/R Follicular Lymphoma
09/26/2024
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a...
09/26/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma
05/16/2024

Amber Denham

Amber Denham
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug...
05/16/2024
Oncology
News
Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma
05/08/2024

Amber Denham

Amber Denham
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective...
05/08/2024
Oncology
FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
News
Prognostic Value of Minimal Residual Disease Among Previously Untreated Patients With Follicular Lymphoma
02/01/2024
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status...
02/01/2024
Oncology
News
Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL
01/22/2024
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested...
01/22/2024
Oncology
News
Mosunetuzumab Yields Clinically Beneficial Outcomes for Patients With Follicular Lymphoma Treated With 3 or More Lines of Therapy
01/19/2024
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that...
01/19/2024
Oncology
News
Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma
01/15/2024
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene...
01/15/2024
Oncology
News
Obinutuzumab Immunochemotherapy Yielded Sustained Improvement in Progression-Free Survival vs Rituximab Among Patients With FL
10/03/2023
Final analysis of the phase 3 GALLIUM trial showed a sustained improvement in progression-free survival with obinutuzumab-based immunochemotherapy compared to rituximab-based immunochemotherapy among patients with previously untreated...
Final analysis of the phase 3 GALLIUM trial showed a sustained improvement in progression-free survival with obinutuzumab-based immunochemotherapy compared to rituximab-based immunochemotherapy among patients with previously untreated...
Final analysis of the phase 3...
10/03/2023
Oncology
News
Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Monotherapy for Patients With R/R Follicular Lymphoma
09/25/2023
Zanubrutinib plus obinutuzumab demonstrated a favorable risk/benefit profile compared with obinutuzumab alone among patients with relapsed/refractory FL, according to results from a phase 2 trial.
Zanubrutinib plus obinutuzumab demonstrated a favorable risk/benefit profile compared with obinutuzumab alone among patients with relapsed/refractory FL, according to results from a phase 2 trial.
Zanubrutinib plus obinutuzumab...
09/25/2023
Oncology

Interactive Features

Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology
Quiz
Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma
03/27/2024
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to...
03/27/2024
Oncology
Quiz
Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy
02/05/2024
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from...
02/05/2024
Oncology
Quiz
Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL
01/29/2024
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the...
01/29/2024
Oncology
Quiz
Predictive Value of Ki67 Expression for Follicular Lymphoma
08/03/2023
True or False: In a study assessing potential predictive biomarkers for follicular lymphoma, results indicated that high follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma...
True or False: In a study assessing potential predictive biomarkers for follicular lymphoma, results indicated that high follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma...
True or False: In a study...
08/03/2023
Oncology
Quiz
Subcutaneous Rituximab for Low-Tumor Burden FL
06/07/2023
True or False: In a study assessing the efficacy and safety of subcutaneous rituximab following induction therapy among patients with low-tumor burden follicular lymphoma, high rituximab exposure during the start of treatment was associated...
True or False: In a study assessing the efficacy and safety of subcutaneous rituximab following induction therapy among patients with low-tumor burden follicular lymphoma, high rituximab exposure during the start of treatment was associated...
True or False: In a study...
06/07/2023
Oncology
Quiz
EZH2 Inhibitor PF-06821497 for Follicular Lymphoma
05/30/2023
True or False: In a study assessing the efficacy and safety of EZH2 inhibitor PF-06821497 among patients with follicular lymphoma, the monotherapy expansion dose was determined to be 75-625 mg twice daily.
True or False: In a study assessing the efficacy and safety of EZH2 inhibitor PF-06821497 among patients with follicular lymphoma, the monotherapy expansion dose was determined to be 75-625 mg twice daily.
True or False: In a study...
05/30/2023
Oncology
Quiz
Quiz: Linperlisib for R/R Follicular Lymphoma
04/25/2023
A study assessing the efficacy and safety of linperlisib for the treatment of relapsed/refractory follicular lymphoma found that patients who received this oral PI3Kδ inhibitor reached an overall response rate of ___.
A study assessing the efficacy and safety of linperlisib for the treatment of relapsed/refractory follicular lymphoma found that patients who received this oral PI3Kδ inhibitor reached an overall response rate of ___.
A study assessing the efficacy...
04/25/2023
Oncology
Quiz
Quiz: Odronextamab Plus Optimized Step-Up Regimen for Follicular Lymphoma
03/31/2023
Patients with R/R follicular lymphoma grade 1 to 3a who received odronextamab plus an optimized step-up regimen reached an overall response of ___.
Patients with R/R follicular lymphoma grade 1 to 3a who received odronextamab plus an optimized step-up regimen reached an overall response of ___.
Patients with R/R follicular...
03/31/2023
Oncology
Quiz
Quiz: Complete Response Rate of Obinutuzumab Plus Lenalidomide For Patients with Follicular Lymphoma
11/09/2022
Obinutuzumab plus lenalidomide demonstrated promising efficacy and safety among patients with previously untreated advanced follicular lymphoma in a recent phase 2 trial, with a primary end point of complete response rate after induction....
Obinutuzumab plus lenalidomide demonstrated promising efficacy and safety among patients with previously untreated advanced follicular lymphoma in a recent phase 2 trial, with a primary end point of complete response rate after induction....
Obinutuzumab plus lenalidomide...
11/09/2022
Oncology

Recent News

News
Odronextamab Demonstrates Durable Responses, Manageable Safety Among Patients With Heavily Pretreated R/R Follicular Lymphoma
09/26/2024
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a phase 2 study, odronextamab therapy achieved deep and durable responses among pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable safety profile.
According to results from a...
09/26/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma
05/16/2024

Amber Denham

Amber Denham
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug...
05/16/2024
Oncology
News
Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma
05/08/2024

Amber Denham

Amber Denham
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective...
05/08/2024
Oncology
FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
News
Prognostic Value of Minimal Residual Disease Among Previously Untreated Patients With Follicular Lymphoma
02/01/2024
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status...
02/01/2024
Oncology
News
Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL
01/22/2024
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.
Recent study results suggested...
01/22/2024
Oncology
News
Mosunetuzumab Yields Clinically Beneficial Outcomes for Patients With Follicular Lymphoma Treated With 3 or More Lines of Therapy
01/19/2024
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that...
01/19/2024
Oncology
News
Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma
01/15/2024
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene...
01/15/2024
Oncology
News
Obinutuzumab Immunochemotherapy Yielded Sustained Improvement in Progression-Free Survival vs Rituximab Among Patients With FL
10/03/2023
Final analysis of the phase 3 GALLIUM trial showed a sustained improvement in progression-free survival with obinutuzumab-based immunochemotherapy compared to rituximab-based immunochemotherapy among patients with previously untreated...
Final analysis of the phase 3 GALLIUM trial showed a sustained improvement in progression-free survival with obinutuzumab-based immunochemotherapy compared to rituximab-based immunochemotherapy among patients with previously untreated...
Final analysis of the phase 3...
10/03/2023
Oncology
News
Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Monotherapy for Patients With R/R Follicular Lymphoma
09/25/2023
Zanubrutinib plus obinutuzumab demonstrated a favorable risk/benefit profile compared with obinutuzumab alone among patients with relapsed/refractory FL, according to results from a phase 2 trial.
Zanubrutinib plus obinutuzumab demonstrated a favorable risk/benefit profile compared with obinutuzumab alone among patients with relapsed/refractory FL, according to results from a phase 2 trial.
Zanubrutinib plus obinutuzumab...
09/25/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use